Antibody-drug conjugates and the use of same in therapy

1. A method for treating a tumor, comprising a step of administering a product of formula IB2 to a subject in need thereof,

wherein

A is an aryl or a cycloalkyl radical, wherein said aryl or cycloalkyl radical is a carbocycle or a heterocycle, or

A is

a

group, a

group or a

group;

X 1 is a C═O or an NH group or a single bond;

X 2 is an NH group or a C═O or a single bond;

X 3 is an oxygen or a single bond;

s is equal to 1, 2 or 3,

r is equal to 0, 1 or 2, wherein r+s is equal to 3;

n 1 is an integer equal to 0 or 1; n 2 is an integer equal to 1, 2 or 3 and n 3 is an integer equal to 1, 2 or 3;

n 4 is an integer equal to 1, 2, 3 or 4;

L is a linker;

M is a cytotoxic drug selected from a chemotherapeutic agent or a toxin;

P is a protein comprising at least one disulphide bridge; and

t is an integer from 1 to 15.

2. The method of claim 1 , wherein M is monomethyl auristatin E or monomethyl auristatin F.

3. The method of claim 1 , wherein the

group is selected from

wherein each of T, Y and Z are independently carbon or nitrogen.

4. The method of claim 3 , wherein T is a nitrogen atom, and Y and Z represent CH.

5. The method of claim 1 , wherein -L-M corresponds to general formula III, IIIa or IIIb:

wherein:

K is a

radical,

wherein the

radical is a sequence of n 5 amino acids, wherein said n 5 amino acids are identical or different, natural or non-natural, or

a hydrazino radical optionally coupled to the

radical, or

a saccharide group;

X is a hydrogen or an NO 2 group,

Y is a

chain or a single bond or a spacer, optionally interrupted by one or more oxygen, sulfur or nitrogen atoms, and

n 5 is an integer from 1 to 6.

6. The method of claim 5 , wherein the saccharide group is selected from a beta-glucuronic acid, a beta-D-galactose, a beta-D-glucose, an alpha-D-mannose, an N-acetyl-D-glucosaminyl, an N-acetyl-D-galactosaminyl, a D-glucuronyl, an L-iduronyl, a D-glucopyranosyl, a D-galactopyranosyl, a D-mannopyranosyl or L-fucopyranosyl.

7. The method of claim 5 , wherein the spacer is selected from a linear or branched alkyl radical having from 1 to 30 carbon atoms, optionally interrupted by one or more oxygen, sulphur or nitrogen atoms.

8. The method of claim 5 , wherein the spacer is polyethylene glycol.

9. The method of claim 5 , wherein n 5 in the

radical is an integer from 1-5.

10. The method of claim 9 , wherein the integer is 2 or 3.

11. The method of claim 5 , wherein AA in the

radical is a valine and a citrulline; a phenylalanine and a lysine; a valine and an aspartic acid; a lysine and a methionine; a lysine and an asparagine; a proline and an isoleucine; a proline and a lysine; a valine and a lysine; an alanine and a lysine; a phenylalanine and a lysine; two phenylalanines and a lysine; an alanine, a phenylalanine and a lysine; two arginines; a lysine and an arginine; a glutamic acid, a glycine and an arginine; or two glycines and an arginine.

12. The method of claim 1 , wherein M is a chemotherapeutic agent selected from the group consisting of duocarmycin, dolastatins, combretastatin, calicheamicin, N-acetyl-γ-calicheamycin (CMC), maytansine, DM-I, auristatin E, auristatin EB (AEB), auristatin EFP (AEFP), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), tubulysin, disorazole, an epothilone, Paclitaxel, docetaxel, Topotecan, echinomycin, estramustine, cemadotine, eleutherobin, methopterin, actinomycin, daunorubicin, a daunorubicin conjugate, mitomycin C, mitomycin A, vincristine, retinoic acid, camptothecin, SN38, maytansine, DM1, DM4, TK1, amanitin, a pyrrolobenzodiazepine, a pyrrolobenzodiazepine dimer, methotrexate, ilomedine, aspirin, an IMID, lenalidomide and pomalidomide.

13. The method of claim 1 , wherein M is a toxin selected from pseudomonas exotoxin (PE), deBouganin, Bouganin, diphtheria toxin (DT) and ricin.

14. The method of claim 1 , wherein P is an antibody, an antibody fragment or a fusion protein comprising an antibody or an antibody fragment.

15. The method of claim 1 , wherein P is an antibody or an antibody fragment, wherein the antibody or fragment is chimeric, humanized, human, monospecific or bispecific.

16. The method of claim 1 , wherein P is the antibody fragment selected from the group consisting of Fab, F(ab)′2, Fc, F′c, pFc′, ScFv, Fv, Fd, Fabc, diabody, minibody, ScFv-Fc and ScFv-Fv.

17. The method of claim 1 , wherein P is an antibody or antibody fragment directed against a tumor antigen.

18. The method of claim 1 , wherein P is an antibody or an antibody fragment directed against

(i) a cluster of differentiation (CD) antigen selected from CD1a, CD3, CD4, CD13, CD19, CD20, CD21, CD22, CD25, CD30, CD31, CD33, CD34, CD37, CD39, CD40, CD44, CD47, CD52, CD56, CD66e, CD70, CD72, CD73, CD74, CD79, CD79b, CD80, CD86, CD117, CD138, CD194, CD205, CD227, CD248 or CD363; or

(ii) an antigen selected from the group consisting of CA125, G250, GD2, HLA-DRβ, MUC1, VEGF, VEGFA, VEGF-R1/2, TRAIL-R2 (DR5), EpCAM, GPIIb, GPIIIa, TNF alpha, TNFR, TNT, Lewis Y, EGFR, HER-2, HER-3, HER-3 MM-111, HER-4, homodimer or heterodimer between members of the erbbn family, wherein n is an integer between 1 and 4, AXL, Protein F, IgE-Fc, VEGF-A, integrin 4, integrin alpha4beta7, integrin alphaV, C5, IL-6R, IL-6Ralpha, IL12, IL15, IL18, IL23, IL-1beta, IL-1, TPO-R, GPNMB, PSMA, PSA, PAP, PSM, integrin alphav, Cripto, TACSTD2, CEA, Folate receptor 1, Mucin 16, Endothelin Receptor ETB, STEAP1, SLC44A4 (AGS-5), Nectin 4, AGS-16, Guanylyl cyclase C, Mucin 1, EGFRvIII, Mesothelin, IL2R, A33, Can, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGFR-1, VEGFR-2, VEGFR-3, TGFbeta, TGFbetaR, FGF, FGF8b, FGFR, PDGF, PDGFR, PDGFRalpha, PDGFRbeta, Ang-1, Ang-2, integrin, α2β1, alpha-v-beta3, alpha-v-beta5, alpha3beta1, alpha6beta4, alpha2beta1, anti-integrin alpha4, RANK-L, BLyS, c-MET, DR, DR10, TCRalpha, beta, ICOS, CTLA-4, CAIX (MN), EphA2, CA6, ovarian CA6, cervical CA6, breast CA6, angiopoietin-2, Cripto, ENPP3, Mesothelin, FOLR1, Nectin-4, TIM-1, Muc-16, Tissue Factor, LIV-1, GM2, alpha5 integrin, TLR-7, PD-1, AFP, CA125 (MUC16), Sialyl Lewis Y , CAMPATH-1, HLA-DR, anti-idiotype, carcinoembryonic antigen (CEA), TAG-72, Folate-binding protein, A33, G250, a ganglioside, Le Y , collagen 4 (collagen IV), collagen 18 (collagen XVIII), SC6, CA-125, CA19-9, p185 HER2 , de2-7 EGFR, Fibroblast activation protein (FAP), Tenascin, metalloproteinases, Endosialin, Carbonic anhydrase, Galectin 9, Aldolase A, eIFgamma4, Tyrosinase, Galectin 4, HERKV-K10, p53, NY-LU-12, Restin, NY-CO-38, MAGE-1, MAGE-4a, SSX2, NY-ESO-1, SCP-1, HGFR, PTK 7, CCK-4, PDGFR, PTP-LAR, CDCP1, CADM1, IGSF4, Lu, BCAM, CEACAM6, JAM-A, PTGFRN (CD9P-1), MCAM, MUC18, MCP, EMMPRIN, TfR, TRAILR2, C1qR, hTERT, Survivin, MDM2, CYP1B1, Melan-A, MART-1, MART-2, Melanosomal proteins, gp100, neo-PAP, CDC27, MAGEs, WT1, MUM-1, MUM-2, MUM-3, BRAF, TPI, fibronectin, K-ras, beta-catenin, CDK4, caspase-8, p14 ARF , p16 INK4a , bcr-ab1, SYT-SSX, TRP-1, TRP-2, GnT-V, tyrosinase, FGF5, TEL-AML1, proteinase 3, HER2/neu, AFP, MUC-1, EBV-EBNA, HTLV-1 tax, HPV16-E7, mutated HLA-A2, HA1, SART3, GnT-V, CEACAM5, AGS-16, GPNMB, ESAT-6, RANK, CanAg, fibrin, TF, PRAME, CA19-9, CA50, CA125, CA195, CAM17.1/WGA, AFP, beta-MG, DU-PAN2, HE4, b-2 microglobulin, transferrin, transthyretin, ApoA1, TROP-2, CTLA-4, GITR, PD-1, PD-L1, c-KIT, CD11b-CD18 integrin heterodimer, DNA/Histon H1, Folate, EpCAM, Tenascin-c, Extracellular Matrix (ECM), fibrinogen, SV40 large T antigen, SC6-Ag, SC—Ag, death receptor 4 (DR4), DR5, ESA, mucin, hPAM4, hRS7, HLA-DR, CCR4, PECAM, thrombomodulin, Tn, cathepsin D, TYRO-3, MER or a PF4/heparin complex.

19. The method of claim 18 , wherein TACSTD2 is TROP2 and/or EGP1, wherein the ganglioside is GD2, GD3 and/or GM2, or wherein the ECM is proteoglycan and/or fibronectin.

20. The method of claim 1 , where the tumor is a colorectal cancer, a hepatocarcinoma, a lung cancer, a pancreatic cancer, a breast cancer, a liver cancer, a head and neck cancer, a Castleman disease tumor, a thyroid cancer, a medulloblastoma, a glioblastoma multiforme, a glioma, a sarcoma, an anaplastic astrocytoma, a kidney cancer, a stomach cancer, malignant ascites, a metastatic prostate cancer, a non-metastatic prostate tumor, a solid tumor, a leukemia, a melanoma, a myeloma, or a lymphoma.

21. The method of claim 20 , wherein the breast cancer is a triple-negative breast cancer or a metastatic breast cancer, wherein the leukemia is acute myeloid leukemia or chronic lymphocytic leukemia, wherein the lymphoma is mantle cell lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma or follicular lymphoma, wherein the myeloma is multiple myeloma, wherein the lung cancer is not a small cell lung cancer or wherein the colorectal cancer is a K-RAS mutated colorectal cancer.

22. The method of claim 20 , wherein the lung cancer is a small cell lung cancer.

23. The method of claim 20 , wherein the lung cancer is not a small cell lung cancer.

24. The method of claim 1 , wherein t is an integer from 1 to 13.

25. The method of claim 1 , wherein t is an integer from 1 to 6.